文献速递免疫规划

伤寒合成Vi多糖疫苗的研制

Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
PubMed 文献 · Vaccine · 2017-11-14

为应对现有Vi荚膜多糖疫苗效力有限且生产工艺复杂的问题,研究者制备了O-乙酰化高分子量聚半乳糖醛酸(GelSite-OAc™),其主链与伤寒沙门菌Vi多糖相同。在Balb/c小鼠中,GelSite-OAc™呈现O-乙酰化程度和剂量依赖的强免疫原性,诱导的抗体水平与已上市Vi疫苗相当或更高,对致死性攻击完全保护,且二次免疫后抗体水平升高>2倍。

要点

  • GelSite-OAc™分子量>1×10⁶ Da、O-乙酰化程度>5 μmol/mg,均超过现行Vi疫苗效力标准。
  • GelSite-OAc™在小鼠中诱导的抗体应答呈O-乙酰化程度和剂量依赖,与已上市Vi疫苗相当或更高。
  • GelSite-OAc™对伤寒沙门菌致死性攻击完全保护,二次免疫后抗体水平升高>2倍。

核心结论

  • GelSite-OAc™可能成为针对伤寒沙门菌的高效疫苗。

研究设计与样本

  • 研究在Balb/c小鼠中评价新型合成O-乙酰化高分子量聚半乳糖醛酸(GelSite-OAc™)的免疫原性、保护效力及记忆应答。

主要发现

  • GelSite-OAc™分子量>1×10⁶ Da,O-乙酰化程度>5 μmol/mg,均超过现行Vi疫苗效力标准。
  • GelSite-OAc™在小鼠中呈O-乙酰化程度和剂量依赖的强免疫原性,诱导的抗原特异性抗体应答与已上市Vi疫苗相当或更高。
  • GelSite-OAc™对伤寒沙门菌致死性攻击提供完全保护。
  • 第二次免疫GelSite-OAc™或Vi疫苗后抗体水平升高>2倍,显示加强或记忆应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid fever remains a serious public health problem with a high impact on toddlers and young children. Vaccines against the Vi capsular polysaccharide are efficacious against typhoid fever demonstrating that antibodies against Vi confer protection. The currently licensed Vi typhoid vaccines have however limited efficacy and are manufactured by a complex process from wild-type bacteria. Due to these inherent issues with the current vaccines, an alternative vaccine based on an O-acetylated high molecular weight (HMW) polygalacturonic acid (GelSite-OAc™) was generated. The HMW polygalacturonic acid shares the same backbone as the Vi polysaccharide of Salmonella Typhi. The GelSite-OAc™ has a high molecular weight (>1 × 106 Da) and a high degree of O-acetylation (DOAc) (>5 μmole/mg), both exceeding the potency specifications of the current Vi vaccine. Studies in Balb/c mice demonstrated that GelSite-OAc™ was highly immunogenic, inducing a strong antigen-specific antibody response in a DOAc- and dose-dependent manner which was comparable to or higher than those induced by the licensed Vi vaccine. Importantly, the GelSite-OAc™ was shown to be fully protective in mice against lethal challenge with Salmonella Typhi. Furthermore, the GelSite-OAc™ demonstrated a boosting effect or memory response, exhibiting a >2-fold increase in antibody levels upon the second immunization with either GelSite-OAc™ or the Vi vaccine. This novel boosting effect is unique among polysaccharide antigens and potentially makes GelSite-OAc™ effective in people under 2 years old. Together these results suggest that the GelSite-OAc™ could be a highly effective vaccine against Salmonella Typhi.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017. PMID: 29150208. doi:10.1016/j.vaccine.2017.10.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。